This resource from the American Society for Addiction Medicine (ASAM) gives guidance on providing access to buprenorphine for patients treated for opioid use disorder in primary care and outpatient settings during the COVID-19 pandemic. It includes recommendations on using telemedicine options to connect with patients, advice on prescriptions and refills and ensuring adequate supply of medication, guidance on eliminating requirements for psychosocial treatment or counseling, recommendations for speaking with patients about harm reduction and ensuring access to naloxone, and considerations for high-risk patients.
Funding Source: American Society of Addiction Medicine
COVID-19: Supporting Access to Buprenorphine
Guidance from the American Society of Addiction Medicine for clinicians providing buprenorphine treatment for opioid use disorder during the COVID-19 pandemic